Source: Times of India
NEW DELHI: Limited use of hydroxychloroquine (HCQ) for treatment of Covid-19 patients was allowed as it has proved to be clinically beneficial in small single centre studies, the Centre told Parliament on Tuesday, reports Mohua Chatterjee.
Junior health minister Ashwini Choubey was replying to a question on whether the government had accurate data regarding efficacy of HCQ .
The minister said, “The government has re-purposed the drug HCQ for treatment of mild (but high-risk cases) and for moderate cases. However, the drug is not recommended for severe cases and those with pre-existing cardiac disease… . ”
He said the ministry does not maintain data on using patterns of HCQ by doctors, nurses, health workers and other front-line corona warriors.
The minister gave state-wise break-up on details of HCQ supplied by the government and actual consumption and said that “India has exported the drug to more than 140 countries.”
Study to commence: Hydroxychloroquine plus personal protective equipment versus standard personal protective equipment alone for the prevention of COVID-19 infections among frontline healthcare workers: the Hydroxychloroquine Prophylaxis Evaluation(HOPE) trial: A structured summary of a study protocol for a randomized controlled trial